Trial record 1 of 1 for:    NCT02495103
Previous Study | Return to List | Next Study

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02495103
Recruitment Status : Recruiting
First Posted : July 13, 2015
Last Update Posted : March 22, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 1, 2021
  Estimated Study Completion Date : May 1, 2022